{"schema_version":"1","generated_at":"2026-10-30T21:25:03.849Z","data_as_of":null,"url":"https://www.findmykol.com/kol/soravis-osataphan","json_url":"https://www.findmykol.com/kol/soravis-osataphan/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"soravis-osataphan","name":"Soravis Osataphan","specialty":"Medical Oncology","specialty_raw":"Medical Oncology","therapeutic_area":"Oncology","therapeutic_areas":["Oncology"],"institution":"Broad Institute","institution_url":"https://www.findmykol.com/institution/broad-institute","city":"Boston","state":"MA","region":{"label":"Northeast","url":"https://www.findmykol.com/region/northeast"}},"identifiers":{"npi":"1164086518","orcid":"0000-0002-6503-4418","openalex":"A5079622150"},"summary":"Soravis Osataphan is an Oncology physician affiliated with Broad Institute. OpenAlex indexes 49 publications with 453 citations (h-index 9).","overview":null,"focus":{"indications":[],"research_topics":["Oncology"]},"scholarship":{"works_count":49,"cited_by_count":453,"h_index":9,"latest_activity_year":2026,"source":"works"},"payments":{"company_count":1,"program_years":{"first":2021,"last":null},"rows_total":1,"shown":1,"withheld":0,"rows":[{"payer":"JAZZ PHARMACEUTICALS INC.","program_year":2025,"amount_usd":163.91,"payment_count":2,"source_url":"https://openpaymentsdata.cms.gov/search?query=1164086518"}],"record_url":"https://openpaymentsdata.cms.gov/search?query=1164086518","source":"payments"},"prescribing":{"data_year":2024,"areas_total":3,"areas_shown":3,"areas":[{"area":"Cancer & immunology","share_pct":46.9,"classes_total":2,"classes":[{"class":"Poly(ADP-Ribose) Polymerase Inhibitor","setting":"prescribed","share_pct":24.5,"drugs":[{"name":"Lynparza","share_pct":100}],"max_beneficiaries":null},{"class":"Kinase inhibitor","setting":"prescribed","share_pct":22.4,"drugs":[{"name":"Imatinib Mesylate","share_pct":100}],"max_beneficiaries":null}]},{"area":"Blood & clotting","share_pct":26.5,"classes_total":1,"classes":[{"class":"Factor Xa inhibitor","setting":"prescribed","share_pct":26.5,"drugs":[{"name":"Fondaparinux Sodium","share_pct":100}],"max_beneficiaries":null}]},{"area":"Metabolism & gastrointestinal","share_pct":26.5,"classes_total":1,"classes":[{"class":"Serotonin-3 Receptor Antagonist","setting":"prescribed","share_pct":26.5,"drugs":[{"name":"Ondansetron Odt","share_pct":100}],"max_beneficiaries":null}]}],"source":"medicare"},"publications":{"total":49,"shown":5,"withheld":44,"matched_by":"OpenAlex author record","recent":[{"title":"Chemoimmunotherapy with or without locoregional therapy for biliary tract cancer: A propensity score–matched study.","year":2026,"journal":"Journal of Clinical Oncology","source_url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e16185","status":"verified"},{"title":"The efficacy of rosuvastatin to reduce circulating tissue factor extracellular vesicles after ovarian cancer surgery.","year":2026,"journal":"UNC Libraries","source_url":"https://doi.org/10.17615/kna5-c934","status":"verified"},{"title":"Glucagon-like peptide 1 receptor agonists and venous thromboembolism in type 2 diabetes: a target trial emulation","year":2025,"journal":"Blood Advances","source_url":"https://doi.org/10.1182/bloodadvances.2025015871","status":"verified"},{"title":"Prognostic Role of <i>MTAP</i> Loss in Cholangiocarcinoma","year":2025,"journal":"JCO Precision Oncology","source_url":"https://doi.org/10.1200/po-24-00842","status":"verified"},{"title":"PD-L1 Expression in Biliary Tract Cancer: Comparison Across Antibody Clones and Role as a Predictor of Response to Chemoimmunotherapy: A Meta-Analysis","year":2025,"journal":"JCO Precision Oncology","source_url":"https://doi.org/10.1200/po-24-00475","status":"verified"}],"source":"works"},"contact":{"address_1":"330 BROOKLINE AVE","city":"Boston","state":"MA","zip":"022155400","phone":"617-499-5639","source_url":"https://npiregistry.cms.hhs.gov/provider-view/1164086518","source":"identity"},"similar":[{"name":"Alan Mullen","slug":"alan-mullen","institution":"Broad Institute","specialty":"Gastroenterology","url":"https://www.findmykol.com/kol/alan-mullen","json_url":"https://www.findmykol.com/kol/alan-mullen/profile.json"},{"name":"Benjamin Ebert","slug":"benjamin-ebert","institution":"Broad Institute","specialty":"Hematology","url":"https://www.findmykol.com/kol/benjamin-ebert","json_url":"https://www.findmykol.com/kol/benjamin-ebert/profile.json"},{"name":"Susan Redline","slug":"susan-redline","institution":"Broad Institute","specialty":"Internal Medicine","url":"https://www.findmykol.com/kol/susan-redline","json_url":"https://www.findmykol.com/kol/susan-redline/profile.json"},{"name":"Patrick Ellinor","slug":"patrick-ellinor","institution":"Broad Institute","specialty":"Cardiovascular Disease","url":"https://www.findmykol.com/kol/patrick-ellinor","json_url":"https://www.findmykol.com/kol/patrick-ellinor/profile.json"},{"name":"Carl June","slug":"carl-june","institution":"University of Pennsylvania","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/carl-june","json_url":"https://www.findmykol.com/kol/carl-june/profile.json"},{"name":"Rainer Storb","slug":"rainer-storb","institution":"University of Washington","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/rainer-storb","json_url":"https://www.findmykol.com/kol/rainer-storb/profile.json"},{"name":"Christina Fitzmaurice","slug":"christina-fitzmaurice","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/christina-fitzmaurice","json_url":"https://www.findmykol.com/kol/christina-fitzmaurice/profile.json"},{"name":"Larry Norton","slug":"larry-norton","institution":"Memorial Sloan Kettering Cancer Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/larry-norton","json_url":"https://www.findmykol.com/kol/larry-norton/profile.json"}],"coverage":{"note":"A basic record from the physician directory. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["funding","congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"publications":44}},"sources":{"orcid":{"name":"ORCID","url":"https://orcid.org","provides":"The verified researcher identity that anchors authorship"},"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician","coverage":"Practice location (not mailing) from the NPPES record","record_last_updated":"2025-10-08","provider_certified":"2025-10-08","collected_at":"2026-10-27T00:00:00.000Z"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"},"medicare":{"name":"CMS Medicare Part D Prescribers and Part B","url":"https://data.cms.gov/provider-summary-by-type-of-service","provides":"Share of this prescriber's Medicare fee-for-service prescribing by drug class and therapeutic area, classified with WHO ATC and NLM RxClass","disclaimer":"Proportions of the prescriber's own classified prescribing, never patient counts or dollar amounts. Fee-for-service only; CMS publishes about 17 months after the fact and suppresses counts of ten patients or fewer.","data_year":2024}},"methodology_url":"https://www.findmykol.com/about#methodology"}